Highlights Percheron Therapeutics Limited

Equities

PER

AU0000317281

End-of-day quote Australian S.E. Other stock markets 23:00:00 15/05/2024 BST			5-day change	1st Jan Change
0.074 ^AUD	+1.37%		-2.63%	+25.42%

05-06	WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102	MT
02-28	Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102	05-06	MT
Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23	CI
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK	27/06/23	CI
Antisense Therapeutics Limited Announces the Commencement of Dosing in the Nine-Month Chronic Monkey Toxicology Study of ATL1102	13/03/23	CI
Antisense Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/02/23	CI
Antisense Therapeutics Secures Turkish Clearance for Phase 2 Muscular Dystrophy Trial	14/02/23	MT
Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency	13/02/23	CI
Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency	12/02/23	CI
Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD	31/01/23	CI
Antisense Therapeutics Files Trial Applications for Phase 2b Trial	19/12/22	MT
Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe	18/12/22	CI
Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron	13/11/22	CI
Antisense Therapeutics Receives R&D Rebate of Nearly $580,000	14/10/22	MT
Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study	12/09/22	CI
Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase	07/09/22	CI
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31/08/22	CI
Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets	23/08/22	CI
Antisense Therapeutics Identifies Potential Biomarkers from Long COVID-19 Study; Shares Rise 5%	19/08/22	MT
Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19	19/08/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Percheron Therapeutics Limited

Equities

PER

AU0000317281

Highlights

Filters